FDA
-
-
-
-
-
-
-
Harrow Announces First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
-
-
-
-
-
-
-
ImprimisRx Announces Leadership Changes
-
-
-
-
-
-
-
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
-
-
-
-
-
-
-
Harrow Health (HROW) Announces Transitional Pass-Through Reimbursement Status for TRIESENCE 40 mg/mL
-
-
-
-
-
-
-
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
-
-
-
-
-
-
-
Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products
-
324,763 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

